engasertib

all catalysts(0)

nothing on the calendar yet

News(3)

• Vaderis hauls in $152M to test an AKT-targeting drug
  The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
  biopharma_dive · 7d ago
• Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
  Vaderis is hoping that engasertib will become the first approved medicine for hereditary hemorrhagic telangiectasia, a rare condition that can cause spontaneous bleeding.
  biospace · 7d ago
• ‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
  Vaderis Therapeutics has secured an oversubscribed $152 million series B financing to propel the Swiss biotech's AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rar…
  fiercebiotech · 8d ago